csirt@kutim:~/threat-intel/cve/CVE-2024-47874

Katalog CVE

CVSS 8.7 · High EPSS 0,65%

Kerentanan Allocation of Resources Without Limits or Throttling. Skor CVSS 4.0 8.7 (High) menurut github.com.

Deskripsi (NVD)

Starlette is an Asynchronous Server Gateway Interface (ASGI) framework/toolkit. Prior to version 0.40.0, Starlette treats `multipart/form-data` parts without a `filename` as text form fields and buffers those in byte strings with no size limit. This allows an attacker to upload arbitrary large form fields and cause Starlette to both slow down significantly due to excessive memory allocations and copy operations, and also consume more and more memory until the server starts swapping and grinds to a halt, or the OS terminates the server process with an OOM error. Uploading multiple such requests in parallel may be enough to render a service practically unusable, even if reasonable request size limits are enforced by a reverse proxy in front of Starlette. This Denial of service (DoS) vulnerability affects all applications built with Starlette (or FastAPI) accepting form requests. Verison 0.40.0 fixes this issue.

Rincian

Terbit di NVD
15 Oktober 2024
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 4.0
8.7 (High), sumber github.com
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-770: Allocation of Resources Without Limits or Throttling
EPSS (30 hari)
0,65% peluang dieksploitasi; lebih tinggi dari 49,9% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.